TL;DR: Trulieve Cannabis (TCNNF) tested its 52-week high of $13.28 during Monday’s session before reversing lower in afternoon trade, closing in the $11.76–$11.80 range. The intraday rejection at the 52-week high—representing a near-62% recovery from the $8.20 annual low—creates a technically significant juncture as Trulieve approaches its August 6 Q2 earnings report. With $286.8M in Q1 FY26 revenue and analyst consensus targeting $19.42, the pre-earnings setup warrants close monitoring heading into Tuesday.
Market Analysis
Monday’s cannabis sector session was broadly constructive, with the AdvisorShares Pure US Cannabis ETF (MSOS) closing at $4.49—a 0.67% gain—and extending further in after-hours trade to $4.55 (+1.34%). Against that constructive backdrop, Trulieve Cannabis Corp. (TCNNF) staged one of the most technically notable moves in the MSO universe, briefly touching the $13.28 level to tag a fresh 52-week high before sellers emerged and drove the stock back toward the $11.76–$11.80 range by session end.
That intraday arc—from a $13.09 open through the $13.28 high and back toward $11.76—captures the tension in Trulieve’s chart ahead of a critical near-term catalyst. The $8.20-to-$13.28 range represents a roughly 62% run from the annual low, compressing the float as retail and institutional participants rotate into the name ahead of earnings. Volume for the day came in at 420,590 shares—well below the 2.4 million daily average—meaning Monday’s 52-week high test occurred on thin participation. Low-volume resistance tests that fail to close at session highs often require a second, higher-volume attempt before decisive breakouts materialize.
Trulieve’s market capitalization of approximately $1.64B places it in the same tier as Green Thumb Industries (GTBIF) and Curaleaf Holdings (CURLF), and the $19.42 analyst 1-year price target implies a substantial 47% upside premium relative to Monday’s closing range. The forward narrative remains compelling: Florida market leadership, Q1 revenue of $286.8M establishing the revenue baseline, and the potential for 280E tax relief to dramatically alter the profitability profile upon any Schedule III rescheduling resolution.
Regulatory and Market Context
Trulieve’s investment thesis is anchored in Florida in ways that cut both ways. The company commands the state’s largest dispensary footprint, making it the primary beneficiary of any adult-use conversion. Florida’s adult-use dynamic remains the single most consequential state-level regulatory catalyst for Trulieve shareholders. While the state legislature has not advanced adult-use legislation in the current cycle, ballot initiative frameworks remain viable paths for the 2026 election cycle and beyond.
On the federal side, the DEA’s administrative law proceeding on Schedule III rescheduling remains the dominant structural catalyst for all MSOs. For Trulieve specifically, 280E relief—which would shift the effective tax burden from the current punitive rate to a normalized corporate rate—represents a potential transformation of per-share earnings. Q1 FY26 showed a profitable $20.2M net income figure even under current 280E conditions, suggesting that Schedule III upside would be additive rather than corrective. Among the major MSOs, Trulieve’s concentrated revenue base means a higher proportional benefit from 280E normalization than more geographically diversified peers.
The sector’s sequential earnings window—GTBIF on August 4, CURLF on August 5, TCNNF on August 6—means Trulieve will report last of the three largest MSOs in a compressed three-day window. This positioning can be a structural advantage: if Green Thumb and Curaleaf report strong Q2 results, Trulieve walks into its earnings call with favorable sector sentiment. Monitor the cannabis stock tracker for real-time updates as the August earnings window approaches.
Conclusion
Monday’s 52-week high test and subsequent intraday reversal in TCNNF presents a technically defined setup for Tuesday’s session. Bulls need to reclaim the $13.28 level on higher-than-average volume to confirm a genuine breakout; failure to do so keeps the stock in a consolidation pattern with support in the $11.23–$11.76 zone. With earnings on August 6 and three sequential MSO reports converging in a four-day window, Trulieve enters the final pre-earnings stretch as one of the highest-conviction catalyst plays in the sector. The combination of Florida optionality, top-line revenue scale, and the structural upside from potential 280E relief creates a multi-layered thesis that the $19.42 analyst consensus price target reflects. Tuesday’s opening session will clarify whether institutional buyers are defending Monday’s reversal or allowing further consolidation before the August earnings event.